Caplin Point rises after its subsidiary gets USFDA nod for generic version of Bloxiverz injection
On Thursday, Caplin Point Laboratories announced that its subsidiary, Caplin Steriles Limited has been granted final approval from United States Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Neostigmine Methylsulfate injection.
The approval from the US regulator was received for the drug in the strengths of 5 mg/10 ml (0.5 mg/ml) and 10 mg/10 ml (1 mg/ml). The drug is the generic therapeutic equivalent version of Bloxiverz injection of Exela Pharma Sciences and is a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarising neuromuscular blocking agents (NMBAs) after surgery.
According to data from IMS Health, Neostigmine Methylsulfate injection had US sales data of approximately US$ 20 million for the 12-month period ending December 2020.
The shares of Caplin Point Laboratories closed at Rs 521.70, up by 2.86 per cent or Rs 14.50 per share, against a 0.79 per cent gain in the benchmark index. The 52-week high of the company is recorded at Rs 686.00 while its 52-week low is Rs 300.10 on BSE.